These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 16112717

  • 1. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
    Rauvala M, Puistola U, Turpeenniemi-Hujanen T.
    Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
    [Abstract] [Full Text] [Related]

  • 2. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A, Höyhtyä M, Tavelin B, Stenling R, Lindmark G.
    Anticancer Res; 2000 Dec; 20(2B):1085-91. PubMed ID: 10810401
    [Abstract] [Full Text] [Related]

  • 3. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
    Määtta M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T, Santala M.
    Anticancer Res; 2007 Dec; 27(4C):2753-8. PubMed ID: 17695443
    [Abstract] [Full Text] [Related]

  • 4. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T.
    Anticancer Res; 2000 Dec; 20(2B):1311-6. PubMed ID: 10810441
    [Abstract] [Full Text] [Related]

  • 5. The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer.
    Rauvala M, Turpeenniemi-Hujanen T, Puistola U.
    Anticancer Res; 2006 Dec; 26(6C):4779-84. PubMed ID: 17214341
    [Abstract] [Full Text] [Related]

  • 6. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
    Honkavuori M, Talvensaari-Mattila A, Puistola U, Turpeenniemi-Hujanen T, Santala M.
    Anticancer Res; 2008 Dec; 28(5A):2715-9. PubMed ID: 19035300
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX, Li L, Li DR, Zhang W, Cheng XQ, Zhang JQ, Tang BJ.
    Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
    [Abstract] [Full Text] [Related]

  • 9. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
    Lengyel E, Schmalfeldt B, Konik E, Späthe K, Härting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W.
    Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
    [Abstract] [Full Text] [Related]

  • 10. Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma.
    Kuvaja P, Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T.
    Hum Pathol; 2006 Oct; 37(10):1316-23. PubMed ID: 16949931
    [Abstract] [Full Text] [Related]

  • 11. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors.
    Jinga D, Stefanescu M, Blidaru A, Condrea I, Pistol G, Matache C.
    Roum Arch Microbiol Immunol; 2004 Oct; 63(3-4):141-58. PubMed ID: 17240786
    [Abstract] [Full Text] [Related]

  • 12. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP, Molenaar IQ, Verspaget HW, Veldman MG, Palareti G, Legnani C, Moolenburgh SE, Terpstra OT, Lamers CB, van Hoek B, Porte RJ.
    Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
    [Abstract] [Full Text] [Related]

  • 13. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
    Salata IM, Stojanovic N, Cajdler-Łuba A, Lewandowski KC, Lewiński A.
    Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
    [Abstract] [Full Text] [Related]

  • 14. Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in the serum of patients with benign and malignant thyroid tumours treated surgically.
    Pasieka Z, Stepien H, Czyz W, Pomorski L, Kuzdak K.
    Endocr Regul; 2004 Jun; 38(2):57-63. PubMed ID: 15497929
    [Abstract] [Full Text] [Related]

  • 15. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J, Banach M, Stolarek RA, Pasnik J, Cialkowska-Rysz A, Koktysz R, Piechota M, Baj Z.
    J Nephrol; 2007 Jun; 20(4):444-52. PubMed ID: 17879211
    [Abstract] [Full Text] [Related]

  • 16. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer.
    Vasala K, Turpeenniemi-Hujanen T.
    Clin Biochem; 2007 Jun; 40(9-10):640-4. PubMed ID: 17374529
    [Abstract] [Full Text] [Related]

  • 17. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
    Klisho EV, Savenkova OV, Kondakova IV, Perel'muter VM, Choĭnzonov EL, Shishkin DA.
    Vopr Onkol; 2007 Jun; 53(1):26-31. PubMed ID: 17649730
    [Abstract] [Full Text] [Related]

  • 18. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.
    Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, Groblewska M, Gryko M, Kedra B, Jurkowska G, Szmitkowski M.
    Pancreas; 2009 Aug; 38(6):613-8. PubMed ID: 19629003
    [Abstract] [Full Text] [Related]

  • 19. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
    Durkan GC, Nutt JE, Rajjayabun PH, Neal DE, Lunec J, Mellon JK.
    Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
    [Abstract] [Full Text] [Related]

  • 20. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
    Durkan GC, Nutt JE, Marsh C, Rajjayabun PH, Robinson MC, Neal DE, Lunec J, Mellon JK.
    Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.